1. Generics Bulletin

Amgen Introduces Second Stelara Rival In Canada

After Alvotech-Jamp Launch, Wezlana Is Billed As First Biosimilar With All Indications

 
• By Dave Wallace

Amgen has launched its Wezlana rival to Stelara in Canada, following up on Jamp and Alvotech’s recent partnered launch of the first Canadian ustekinumab biosimilar, Jamteki, with what Amgen has billed as “the first biosimilar to Stelara to be available for Canadian patients in all indications.”

Canada Flag Boxing Gloves Fight
Two Stelara biosimilars are now competing in Canada • Source: EyeEm / Alamy Stock Photo

Amgen has launched Wezlana (ustekinumab) in Canada, with the product billed by the firm as “the first biosimilar to Stelara to be available for Canadian patients in all indications.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products